Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants. Mt-Isa S, et al. Among authors: hirsch i. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Pharmacoepidemiol Drug Saf. 2014. PMID: 24821575 Review.
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann R, Hobbiger S, Luciani D, Micaleff A, Thomson A, Wang N, van Staa TP, Downey G, Hirsch I, Hockley K, Juhaeri J, Metcalf M, Mwangi J, Nixon R, Peters R, Stoeckert I, Waddingham E, Tzoulaki I, Ashby D, Wise L. Hallgreen CE, et al. Among authors: hirsch i. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):974-83. doi: 10.1002/pds.3676. Epub 2014 Jul 5. Pharmacoepidemiol Drug Saf. 2014. PMID: 25043919 Free article.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants. Mt-Isa S, et al. Among authors: hirsch i. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Pharmacoepidemiol Drug Saf. 2014. PMID: 24821575 Review.
[Morphology of drug induced liver damage].
Kasper HU, Drebber U, Hirsch I, Dienes HP. Kasper HU, et al. Among authors: hirsch i. Pathologe. 2006 May;27(3):175-81. doi: 10.1007/s00292-006-0826-1. Pathologe. 2006. PMID: 16583191 Review. German.
[Adenocarcinoid of the appendix vermiformis].
Hirsch I, Kasper HU, Brabender J, Hölscher AH, Dienes HP. Hirsch I, et al. Pathologe. 2005 May;26(3):231-5. doi: 10.1007/s00292-004-0715-4. Pathologe. 2005. PMID: 15378268 German.
Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials.
Sterner Isaksson S, Imberg H, Hirsch IB, Schwarcz E, Hellman J, Wijkman M, Bolinder J, Nyström T, Holmer H, Hallström S, Ólafsdóttir AF, Pekkari S, Polonsky W, Lind M. Sterner Isaksson S, et al. Among authors: hirsch ib. Diabetologia. 2024 Apr 26. doi: 10.1007/s00125-024-06151-2. Online ahead of print. Diabetologia. 2024. PMID: 38668761
787 results